Interferon-gamma at the crossroads of tumor immune surveillance or evasion
Autor(a) principal: | |
---|---|
Data de Publicação: | 2018 |
Outros Autores: | , , , |
Tipo de documento: | Artigo |
Idioma: | eng |
Título da fonte: | Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos) |
Texto Completo: | https://hdl.handle.net/10216/126500 |
Resumo: | Interferon-gamma (IFN-¿) is a pleiotropic molecule with associated antiproliferative, pro-apoptotic and antitumor mechanisms. This effector cytokine, often considered as a major effector of immunity, has been used in the treatment of several diseases, despite its adverse effects. Although broad evidence implicating IFN-¿ in tumor immune surveillance, IFN-¿-based therapies undergoing clinical trials have been of limited success. In fact, recent reports suggested that it may also play a protumorigenic role, namely, through IFN-¿ signaling insensitivity, downregulation of major histocompatibility complexes, and upregulation of indoleamine 2,3-dioxygenase and of checkpoint inhibitors, as programmed cell-death ligand 1. However, the IFN-¿-mediated responses are still positively associated with patient's survival in several cancers. Consequently, major research efforts are required to understand the immune contexture in which IFN-¿ induces its intricate and highly regulated effects in the tumor microenvironment. This review discusses the current knowledge on the pro- and antitumorigenic effects of IFN-¿ as part of the complex immune response to cancer, highlighting the relevance to identify IFN-¿ responsive patients for the improvement of therapies that exploit associated signaling pathways. |
id |
RCAP_9f491b93a02b07acb60d2193cca040af |
---|---|
oai_identifier_str |
oai:repositorio-aberto.up.pt:10216/126500 |
network_acronym_str |
RCAP |
network_name_str |
Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos) |
repository_id_str |
|
spelling |
Interferon-gamma at the crossroads of tumor immune surveillance or evasionCancer microenvironmentImmune contextureImmunoregulationImmunotherapyType II interferonInterferon-gamma (IFN-¿) is a pleiotropic molecule with associated antiproliferative, pro-apoptotic and antitumor mechanisms. This effector cytokine, often considered as a major effector of immunity, has been used in the treatment of several diseases, despite its adverse effects. Although broad evidence implicating IFN-¿ in tumor immune surveillance, IFN-¿-based therapies undergoing clinical trials have been of limited success. In fact, recent reports suggested that it may also play a protumorigenic role, namely, through IFN-¿ signaling insensitivity, downregulation of major histocompatibility complexes, and upregulation of indoleamine 2,3-dioxygenase and of checkpoint inhibitors, as programmed cell-death ligand 1. However, the IFN-¿-mediated responses are still positively associated with patient's survival in several cancers. Consequently, major research efforts are required to understand the immune contexture in which IFN-¿ induces its intricate and highly regulated effects in the tumor microenvironment. This review discusses the current knowledge on the pro- and antitumorigenic effects of IFN-¿ as part of the complex immune response to cancer, highlighting the relevance to identify IFN-¿ responsive patients for the improvement of therapies that exploit associated signaling pathways.Frontiers Media20182018-01-01T00:00:00Zinfo:eu-repo/semantics/publishedVersioninfo:eu-repo/semantics/articleapplication/pdfhttps://hdl.handle.net/10216/126500eng1664-322410.3389/fimmu.2018.00847Castro, FCardoso, APGonçalves, RMSerre, KOliveira, MJinfo:eu-repo/semantics/openAccessreponame:Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos)instname:Agência para a Sociedade do Conhecimento (UMIC) - FCT - Sociedade da Informaçãoinstacron:RCAAP2023-07-26T15:14:27ZPortal AgregadorONG |
dc.title.none.fl_str_mv |
Interferon-gamma at the crossroads of tumor immune surveillance or evasion |
title |
Interferon-gamma at the crossroads of tumor immune surveillance or evasion |
spellingShingle |
Interferon-gamma at the crossroads of tumor immune surveillance or evasion Castro, F Cancer microenvironment Immune contexture Immunoregulation Immunotherapy Type II interferon |
title_short |
Interferon-gamma at the crossroads of tumor immune surveillance or evasion |
title_full |
Interferon-gamma at the crossroads of tumor immune surveillance or evasion |
title_fullStr |
Interferon-gamma at the crossroads of tumor immune surveillance or evasion |
title_full_unstemmed |
Interferon-gamma at the crossroads of tumor immune surveillance or evasion |
title_sort |
Interferon-gamma at the crossroads of tumor immune surveillance or evasion |
author |
Castro, F |
author_facet |
Castro, F Cardoso, AP Gonçalves, RM Serre, K Oliveira, MJ |
author_role |
author |
author2 |
Cardoso, AP Gonçalves, RM Serre, K Oliveira, MJ |
author2_role |
author author author author |
dc.contributor.author.fl_str_mv |
Castro, F Cardoso, AP Gonçalves, RM Serre, K Oliveira, MJ |
dc.subject.por.fl_str_mv |
Cancer microenvironment Immune contexture Immunoregulation Immunotherapy Type II interferon |
topic |
Cancer microenvironment Immune contexture Immunoregulation Immunotherapy Type II interferon |
description |
Interferon-gamma (IFN-¿) is a pleiotropic molecule with associated antiproliferative, pro-apoptotic and antitumor mechanisms. This effector cytokine, often considered as a major effector of immunity, has been used in the treatment of several diseases, despite its adverse effects. Although broad evidence implicating IFN-¿ in tumor immune surveillance, IFN-¿-based therapies undergoing clinical trials have been of limited success. In fact, recent reports suggested that it may also play a protumorigenic role, namely, through IFN-¿ signaling insensitivity, downregulation of major histocompatibility complexes, and upregulation of indoleamine 2,3-dioxygenase and of checkpoint inhibitors, as programmed cell-death ligand 1. However, the IFN-¿-mediated responses are still positively associated with patient's survival in several cancers. Consequently, major research efforts are required to understand the immune contexture in which IFN-¿ induces its intricate and highly regulated effects in the tumor microenvironment. This review discusses the current knowledge on the pro- and antitumorigenic effects of IFN-¿ as part of the complex immune response to cancer, highlighting the relevance to identify IFN-¿ responsive patients for the improvement of therapies that exploit associated signaling pathways. |
publishDate |
2018 |
dc.date.none.fl_str_mv |
2018 2018-01-01T00:00:00Z |
dc.type.status.fl_str_mv |
info:eu-repo/semantics/publishedVersion |
dc.type.driver.fl_str_mv |
info:eu-repo/semantics/article |
format |
article |
status_str |
publishedVersion |
dc.identifier.uri.fl_str_mv |
https://hdl.handle.net/10216/126500 |
url |
https://hdl.handle.net/10216/126500 |
dc.language.iso.fl_str_mv |
eng |
language |
eng |
dc.relation.none.fl_str_mv |
1664-3224 10.3389/fimmu.2018.00847 |
dc.rights.driver.fl_str_mv |
info:eu-repo/semantics/openAccess |
eu_rights_str_mv |
openAccess |
dc.format.none.fl_str_mv |
application/pdf |
dc.publisher.none.fl_str_mv |
Frontiers Media |
publisher.none.fl_str_mv |
Frontiers Media |
dc.source.none.fl_str_mv |
reponame:Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos) instname:Agência para a Sociedade do Conhecimento (UMIC) - FCT - Sociedade da Informação instacron:RCAAP |
instname_str |
Agência para a Sociedade do Conhecimento (UMIC) - FCT - Sociedade da Informação |
instacron_str |
RCAAP |
institution |
RCAAP |
reponame_str |
Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos) |
collection |
Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos) |
repository.name.fl_str_mv |
|
repository.mail.fl_str_mv |
|
_version_ |
1777304368340533249 |